Mineralys Therapeutics Inc
NASDAQ:MLYS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Opus One Gold Corp
XTSX:OOR
|
CA |
|
B
|
Beijing Asiacom Information Technology Co Ltd
SZSE:301085
|
CN |
Mineralys Therapeutics Inc
Net Income (Common)
Mineralys Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mineralys Therapeutics Inc
NASDAQ:MLYS
|
Net Income (Common)
-$154.7m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-114%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$8.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
133%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
22%
|
|
Mineralys Therapeutics Inc
Glance View
Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
See Also
What is Mineralys Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-154.7m
USD
Based on the financial report for Dec 31, 2025, Mineralys Therapeutics Inc's Net Income (Common) amounts to -154.7m USD.
What is Mineralys Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-114%
Over the last year, the Net Income (Common) growth was 13%. The average annual Net Income (Common) growth rates for Mineralys Therapeutics Inc have been -73% over the past three years , -114% over the past five years .
